Physician profile
Nicolae Leca
NPI 1407931215
$101,463.97
in general payments reported to CMS, 2019-2025
12 companies · $66K in 2025
The $66K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,325 · 2021: $5,670 · 2022: $15K · 2023: $121 · 2024: $8,886 · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Travel and Lodging: $14K · Food and Beverage: $2,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $57,641.74 |
| Travel and Lodging | $14,485.62 |
| Food and Beverage | $2,706.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $22,421.15 | 2024-2025 | Filspari |
| Sanofi-Aventis U.S. LLC | $20,202.66 | 2022-2025 | |
| Veloxis Pharmaceuticals, INC. | $18,324.80 | 2019-2025 | Envarsus |
| Alexion Pharmaceuticals, INC. | $14,112.96 | 2023-2025 | Ultomiris, Strensiq |
| Novartis Pharmaceuticals Corporation | $9,078.50 | 2024-2025 | |
| Argenx US, INC. | $8,571.62 | 2024 | Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $6,045.90 | 2022 | |
| Calliditas Therapeutics US INC. | $2,625.54 | 2024-2025 | Tarpeyo |
| Amgen INC. | $41.59 | 2025 | Tavneos, Uplizna |
| Genzyme Corporation | $39.25 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolae Leca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.